Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML)
is occurring rapidly. Since 2017, nine agents have been approved for various indications in …

The unraveling of the pathophysiology of acute myeloid leukemia (AML) has resulted in
rapid translation of the information into clinical practice. After more than 40 years of slow …

Detection of hallmark genomic aberrations in acute myeloid leukemia (AML) is essential for
diagnostic subtyping, prognosis, and patient management. However, cytogenetic …

Acute myeloid leukemia (AML) is the most common acute leukemia in adults. The
pathophysiology of this disease is just beginning to be understood at the cellular and …

In 2003, an international working group last reported on recommendations for diagnosis,
response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that …

The outlook for patients with acute myeloid leukaemia has improved in the past 30 years.
Unlike other cancers, much of this progress is attributable to refinement of supportive …

For more than 50 years, investigators have considered a malignant stem cell as the potential
origin of and a key therapeutic target for acute myeloid leukemia (AML) and other forms of …

Acute myeloid leukaemia (AML) is a heterogeneous clonal disorder of haemopoietic
progenitor cells and the most common malignant myeloid disorder in adults. The median …

The clinical value of serial minimal residual disease (MRD) monitoring in core binding factor
(CBF) acute myeloid leukemia (AML) by quantitative RT-PCR was prospectively assessed in …

Background Cytarabine (ara-C) is an important drug in the treatment of acute myeloid
leukemia (AML). High-dose cytarabine (2000 to 3000 mg per square meter of body-surface …